Tumor location impacts immune response in mouse models of colon cancer

Xianda Zhao, Lihua Li, Timothy K. Starr, Subbaya Subramanian

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic subcutaneous grafts are problematic, because of increasing evidence that the immune microenvironment in subcutaneous tissue is significantly different from the gastrointestinal tract. Similarly, existing orthotopic models that use a laparotomy for establishing grafts are also problematic, because the surgical procedure results in extensive inflammation, thereby creating a nonphysiologic tumor microenvironment. To facilitate the bench-to-bedside translation of CRC immunotherapy strategies, we developed a novel orthotopic model in mice that uses endoscopy-guided microinjection of syngeneic cancer cells. When we compared immune system infiltration, we found that tumors in the subcutaneous model had fewer T cells, B cells, and natural killer (NK) cells, but more immunosuppressive myeloid cells; in contrast, tumors in our orthotopic model had a higher number of tumor-infiltrating T cells, B cells, and NK cells, with fewer immunosuppressive myeloid cells. The number of immune-stimulating cytokines, such as interleukin (IL)-2, IL-6, interferon (IFN)-gamma, and granzyme B, was also higher in tumors in our model, as compared with the subcutaneous model. Those differences resulted in heightened sensitivity to immune checkpoint blockade therapy in our endoscopy-guided orthotopic CRC model. Our study indicates that tumor location affects immune response in CRC mouse models; choosing the appropriate preclinical model is important when testing immunotherapy in CRC.

Original languageEnglish (US)
Pages (from-to)54775-54787
Number of pages13
JournalOncotarget
Volume8
Issue number33
DOIs
StatePublished - Jan 1 2017

Fingerprint

Colonic Neoplasms
Colorectal Neoplasms
Neoplasms
Myeloid Cells
Immunosuppressive Agents
Natural Killer Cells
Immunotherapy
Endoscopy
B-Lymphocytes
T-Lymphocytes
Transplants
Granzymes
Tumor Microenvironment
Subcutaneous Tissue
Microinjections
Laparotomy
Interferon-gamma
Interleukin-2
Gastrointestinal Tract
Immune System

Keywords

  • Colorectal cancer
  • Immune profiles
  • Immunotherapy
  • Mouse models of cancer
  • Orthotopic models

Cite this

Tumor location impacts immune response in mouse models of colon cancer. / Zhao, Xianda; Li, Lihua; Starr, Timothy K.; Subramanian, Subbaya.

In: Oncotarget, Vol. 8, No. 33, 01.01.2017, p. 54775-54787.

Research output: Contribution to journalArticle

@article{f185373f0bd14244bf0e5d01120344e9,
title = "Tumor location impacts immune response in mouse models of colon cancer",
abstract = "Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic subcutaneous grafts are problematic, because of increasing evidence that the immune microenvironment in subcutaneous tissue is significantly different from the gastrointestinal tract. Similarly, existing orthotopic models that use a laparotomy for establishing grafts are also problematic, because the surgical procedure results in extensive inflammation, thereby creating a nonphysiologic tumor microenvironment. To facilitate the bench-to-bedside translation of CRC immunotherapy strategies, we developed a novel orthotopic model in mice that uses endoscopy-guided microinjection of syngeneic cancer cells. When we compared immune system infiltration, we found that tumors in the subcutaneous model had fewer T cells, B cells, and natural killer (NK) cells, but more immunosuppressive myeloid cells; in contrast, tumors in our orthotopic model had a higher number of tumor-infiltrating T cells, B cells, and NK cells, with fewer immunosuppressive myeloid cells. The number of immune-stimulating cytokines, such as interleukin (IL)-2, IL-6, interferon (IFN)-gamma, and granzyme B, was also higher in tumors in our model, as compared with the subcutaneous model. Those differences resulted in heightened sensitivity to immune checkpoint blockade therapy in our endoscopy-guided orthotopic CRC model. Our study indicates that tumor location affects immune response in CRC mouse models; choosing the appropriate preclinical model is important when testing immunotherapy in CRC.",
keywords = "Colorectal cancer, Immune profiles, Immunotherapy, Mouse models of cancer, Orthotopic models",
author = "Xianda Zhao and Lihua Li and Starr, {Timothy K.} and Subbaya Subramanian",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18423",
language = "English (US)",
volume = "8",
pages = "54775--54787",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "33",

}

TY - JOUR

T1 - Tumor location impacts immune response in mouse models of colon cancer

AU - Zhao, Xianda

AU - Li, Lihua

AU - Starr, Timothy K.

AU - Subramanian, Subbaya

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic subcutaneous grafts are problematic, because of increasing evidence that the immune microenvironment in subcutaneous tissue is significantly different from the gastrointestinal tract. Similarly, existing orthotopic models that use a laparotomy for establishing grafts are also problematic, because the surgical procedure results in extensive inflammation, thereby creating a nonphysiologic tumor microenvironment. To facilitate the bench-to-bedside translation of CRC immunotherapy strategies, we developed a novel orthotopic model in mice that uses endoscopy-guided microinjection of syngeneic cancer cells. When we compared immune system infiltration, we found that tumors in the subcutaneous model had fewer T cells, B cells, and natural killer (NK) cells, but more immunosuppressive myeloid cells; in contrast, tumors in our orthotopic model had a higher number of tumor-infiltrating T cells, B cells, and NK cells, with fewer immunosuppressive myeloid cells. The number of immune-stimulating cytokines, such as interleukin (IL)-2, IL-6, interferon (IFN)-gamma, and granzyme B, was also higher in tumors in our model, as compared with the subcutaneous model. Those differences resulted in heightened sensitivity to immune checkpoint blockade therapy in our endoscopy-guided orthotopic CRC model. Our study indicates that tumor location affects immune response in CRC mouse models; choosing the appropriate preclinical model is important when testing immunotherapy in CRC.

AB - Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic subcutaneous grafts are problematic, because of increasing evidence that the immune microenvironment in subcutaneous tissue is significantly different from the gastrointestinal tract. Similarly, existing orthotopic models that use a laparotomy for establishing grafts are also problematic, because the surgical procedure results in extensive inflammation, thereby creating a nonphysiologic tumor microenvironment. To facilitate the bench-to-bedside translation of CRC immunotherapy strategies, we developed a novel orthotopic model in mice that uses endoscopy-guided microinjection of syngeneic cancer cells. When we compared immune system infiltration, we found that tumors in the subcutaneous model had fewer T cells, B cells, and natural killer (NK) cells, but more immunosuppressive myeloid cells; in contrast, tumors in our orthotopic model had a higher number of tumor-infiltrating T cells, B cells, and NK cells, with fewer immunosuppressive myeloid cells. The number of immune-stimulating cytokines, such as interleukin (IL)-2, IL-6, interferon (IFN)-gamma, and granzyme B, was also higher in tumors in our model, as compared with the subcutaneous model. Those differences resulted in heightened sensitivity to immune checkpoint blockade therapy in our endoscopy-guided orthotopic CRC model. Our study indicates that tumor location affects immune response in CRC mouse models; choosing the appropriate preclinical model is important when testing immunotherapy in CRC.

KW - Colorectal cancer

KW - Immune profiles

KW - Immunotherapy

KW - Mouse models of cancer

KW - Orthotopic models

UR - http://www.scopus.com/inward/record.url?scp=85029056389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029056389&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18423

DO - 10.18632/oncotarget.18423

M3 - Article

C2 - 28903381

AN - SCOPUS:85029056389

VL - 8

SP - 54775

EP - 54787

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -